RESUMEN
Low birth weight and length for gestational age are associated with a high risk of short stature and metabolic syndrome in adulthood. The mechanisms that link prenatal growth to adult stature and metabolic syndrome have not yet been entirely clarified. The aim of our study was to evaluate the relationship between standardized anthropometric measures at birth and insulin-like growth factor (IGF)-I, IGF-II, insulin, adiponectin, and non-esterified fatty acid (NEFA) cord blood levels in the general population. One hundred fifty-eight random newborn subjects (77F, 81M) from Genoa, Italy, were analyzed. Anthropometric parameters were measured and standardized according to standard Italian tables. Insulin values were treated as categorical, since in several cases the results fell below detection cut-off. Mean birth weight was 3,214.23∓488.99 gr and mean length was 49.82∓2.17 cm. Females had higher mean IGF-I (p=0.04), and were more likely to have insulin values either <2 μU/ml or >4.5μU/ml (p= 0.04) compared to males. Weight and length SD scores (SDS) were higher in subjects with elevated insulin levels (p=0.002). A moderate correlation was found between weight and IGF-II (r=0.354). Multivariable analysis demonstrated that standardized birth weight was associated with IGFII and insulin values. Our data highlight the importance of IGF-II in fetal growth and suggest that gender differences should be taken into consideration when evaluating prenatal growth.
Asunto(s)
Peso al Nacer , Estatura , Ácidos Grasos no Esterificados/sangre , Péptidos y Proteínas de Señalización Intercelular/sangre , Adulto , Biomarcadores/sangre , Femenino , Humanos , Recién Nacido de Bajo Peso , Recién Nacido , Masculino , Síndrome Metabólico/sangre , Factores de RiesgoAsunto(s)
Antifúngicos/administración & dosificación , Antifúngicos/farmacocinética , Candidiasis Invasiva/tratamiento farmacológico , Equinocandinas/administración & dosificación , Equinocandinas/farmacocinética , Lipopéptidos/administración & dosificación , Lipopéptidos/farmacocinética , Quimioterapia de Mantención/métodos , Adolescente , Humanos , Masculino , MicafunginaRESUMEN
The aim of this work is to compare the results of a commercially available liquid chromatography tandem mass spectrometry (LC-MS/MS) method in a clinical pathology laboratory for routine Therapeutic Drug Monitoring (TDM) of cyclosporine (CsA) and tacrolimus (Tacr) in pediatric patients with those obtained with the current antibody-conjugated magnetic immunoassay (ACMIA). Whole blood levels of CsA (n= 135) and Tacr (n=100) were sequentially analyzed by using ACMIA and LC-MS/MS on pediatric transplanted patients. The differences were analyzed by using the Passing Bablok regression analysis and the Bland and Altman test. The LC-MS/MS method showed excellent reproducibility and lower limits of quantification compared to the ACMIA. A linear relationship between ACMIA and LC-MS/MS was obtained for both CsA Tacr. No significant inter-method biases were observed. The analytical performances of the LC-MS/MS method make it suitable for the accurate measurement of CsA and Tacr in pediatric transplanted patients. However ACMIA results are also accurate and reliable. For this reason the choice of the method to be used in a routine clinical pathology laboratory can be made on the bases of non-analytical considerations such as costs, organization, availability of skilled personnel.
Asunto(s)
Anticuerpos , Cromatografía Liquida , Ciclosporina/sangre , Monitoreo de Drogas/métodos , Inmunoensayo , Inmunosupresores/sangre , Magnetismo , Tacrolimus/sangre , Espectrometría de Masas en Tándem , Factores de Edad , Trasplante de Médula Ósea , Humanos , Trasplante de Riñón , Límite de Detección , Modelos Lineales , Valor Predictivo de las Pruebas , Reproducibilidad de los ResultadosRESUMEN
Therapeutic drug monitoring (TDM) of major metabolites of thiopurine drugs is a widely used tool for assessing treatment efficacy and toxicity in patients with inflammatory bowel disease (IBD). We report the laboratory and clinical validation of a simple and reliable high performance liquid chromatography (HPLC) method for the measurement of 6-thioguanine nucleotides (6-TGN) and 6-methylmercaptopurine (6-MMP) on paediatric patients with IBD. The aim of this paper is to develop and validate a method for the measurement of 6-TGN and 6-MMP applicable to routine practice and to evaluate the usefulness of the TDM of thiopurine drugs in children with IBD attending our Gastroenterology Unit. The HPLC method was validated following international guidelines starting from red blood cells (RBC) and whole blood (WB). A comparison between RBC and WB was assessed. The usefulness of TDM was then evaluated using the new method from WB in 47 paediatric patients with IBD treated with thiopurine drugs. WB and RBC resulted in interchangeable matrices. The majority of patients had the metabolite levels inside the therapeutic ranges. A moderate correlation was found between 6-MMP concentration and the dose of thiopurines. A higher percentage of non responders was found among patients with lower levels of 6-TGN. Toxicity was found in eight patients and was evaluated in respect to the metabolite concentration. The described HPLC method is applicable to routine practice and it is suitable for its use in multicentric studies. Our results of TDM on paediatric IBD patients can contribute to clarify its role in their therapeutic management.
Asunto(s)
Antiinflamatorios/farmacocinética , Cromatografía Líquida de Alta Presión , Monitoreo de Drogas/métodos , Fármacos Gastrointestinales/farmacocinética , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Mercaptopurina/análogos & derivados , Tioguanina/farmacocinética , Adolescente , Factores de Edad , Antiinflamatorios/sangre , Antiinflamatorios/uso terapéutico , Biotransformación , Niño , Preescolar , Eritrocitos/metabolismo , Femenino , Fármacos Gastrointestinales/sangre , Fármacos Gastrointestinales/uso terapéutico , Humanos , Lactante , Enfermedades Inflamatorias del Intestino/sangre , Italia , Masculino , Mercaptopurina/sangre , Mercaptopurina/farmacocinética , Mercaptopurina/uso terapéutico , Reproducibilidad de los Resultados , Tioguanina/sangre , Tioguanina/uso terapéuticoRESUMEN
This open prospective study aims to evaluate whether a therapy with a polyvalent mechanical bacterial lysate (PMBL) could be associated to the enhancement of the locoregional immunoresponse in patients with recurrent upper respiratory tract infections. Forty patients (23 females and 17 males) were enrolled, 33 of whom concluded the study. The duration of the study was six months and each patient was visited five times. Twenty-six patients had an objective improvement in clinical and medical locoregional conditions, while in seven patients the treatment did not result in an objective amelioration. Twenty-five out of 27 patients with clinical response were characterized by an increase of specific antibodies against PMBL antigens in salivary fluids. Only two patients, with a non-significant clinical result, had a slight increase in the concentration of salivary specific IgA. The association between PMBLspecific immunoglobulin titers and clinical results was significant for IgG and IgA, but not significant for IgM. Th1 switch was detected only in patients with clinical amelioration, while the Th0 phenotype was observed in three responder and four non-responder patients. Weak Th2 polarization was also observed in one clinical responsive patient. The capacity of effectively opsonizing living bacteria was detected in samples derived from responder patients. These results suggest that PMBL treatment was able to trigger an efficient and well-targeted immune-response resulting in positive clinical outcome of the patients treated.
Asunto(s)
Bacterias/química , Mezclas Complejas/administración & dosificación , Mezclas Complejas/química , Inmunidad Mucosa/efectos de los fármacos , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Infecciones del Sistema Respiratorio/inmunología , Adolescente , Adulto , Anciano , Femenino , Humanos , Inmunidad Mucosa/inmunología , Inmunoglobulinas/sangre , Inmunoglobulinas/inmunología , Inmunoterapia/métodos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Infecciones del Sistema Respiratorio/sangre , Saliva/inmunología , Saliva/metabolismo , Células TH1/inmunología , Células TH1/metabolismo , Células Th2/inmunología , Células Th2/metabolismoRESUMEN
In this study we have evaluated the modifications of matrix metalloproteinases (MMPs) in malignant pleural fluids taken from patients suffering from lung cancer and treated with intrapleural talc instillation to induce pleurodesis. Furthermore, we have analysed the variations of some inflammatory mediators (C-reactive protein, alpha-1 antitrypsin) and of a protein (plasminogen) involved in MMP activation. In all patients the clinical improvement after talc pleurodesis was followed by a reduction in MMP-1, TIMP-1, C-reactive protein, alpha-1 antitrypsin and plasminogen activity. Furthermore, MMP-9 levels were variable; in fact, in some patients they were high at the beginning of treatment, in others they increased a few days after pleurodesis induction. These inhibitory effects of talc on MMP-1 and inflammatory mediators associated with the reduction of pleural effusion could constitute an effective means to evaluate the evolution of the treatment.
Asunto(s)
Metaloproteinasas de la Matriz/metabolismo , Derrame Pleural Maligno/terapia , Pleurodesia , Talco/administración & dosificación , Anciano , Proteína C-Reactiva/análisis , Proteína C-Reactiva/metabolismo , Femenino , Humanos , Masculino , Metaloproteinasa 1 de la Matriz/análisis , Metaloproteinasa 1 de la Matriz/metabolismo , Metaloproteinasa 9 de la Matriz/análisis , Metaloproteinasa 9 de la Matriz/metabolismo , Persona de Mediana Edad , Plasminógeno/análisis , Plasminógeno/metabolismo , Derrame Pleural Maligno/enzimología , Derrame Pleural Maligno/inmunología , Estadísticas no Paramétricas , Inhibidor Tisular de Metaloproteinasa-1/análisis , Inhibidor Tisular de Metaloproteinasa-1/metabolismo , alfa 1-Antitripsina/análisis , alfa 1-Antitripsina/metabolismoRESUMEN
Natural killer (NK) cells have the capability of lysing targets that have down-regulated the expression of HLA class I molecules. Herpes simplex virus (HSV) infection results in a profound reduction of HLA class I molecules on the surface of infected cells. For this reason, NK cell populations kill efficiently HSV-infected cells. The recent availability of a panel of monoclonal antibodies directed to NK receptors for HLA class I (CD158a, CD158b, anti-p70, anti-p140, and CD94) allowed an accurate dissection of the NK cell subpopulations. Using this approach, the relationship between the expression of NK cell receptors and the capability of lysing HSV-infected cell targets was analyzed at the clonal level. NK cell clones were derived from healthy donors, and cytolytic properties were assayed against HSV-infected autologous fibroblasts. NK cell clones, classified according to the expression of natural killer-cell receptors on their surface, displayed a great heterogeneity of cytolytic properties against HSV-infected cells. Nevertheless, a more accurate functional analysis demonstrated not only that HSV infection downregulated the expression of HLA-A and HLA-B and did not modify the expression of HLA-C, but also that NK cell clones expressing the "activating" form of the anti HLA-C NK cell receptor were more cytolytic than other clones. This finding suggests that two different and clonally distributed mechanisms of NK cell activation may be employed by NK cells to kill HSV-infected autologous target cells.
Asunto(s)
Células Asesinas Naturales/inmunología , Simplexvirus/inmunología , Células Cultivadas , Células Clonales , Citotoxicidad Inmunológica , Fibroblastos , Fluorescencia , Antígenos HLA-A/análisis , Antígenos HLA-B/análisis , Antígenos HLA-C/análisis , Humanos , Inmunidad Celular , Células Asesinas Naturales/metabolismo , Activación de Linfocitos , Receptores Inmunológicos/metabolismoRESUMEN
Interferons upregulate the expression of HLA class I antigens on cancer cells. Nevertheless, little is known about the panel of HLA class I antigen-associated peptides presented by recombinant alpha-interferon (r(alpha)-IFN)-treated cells. For this reason, peptides were eluted from five cancer cell lines (four melanoma and one non-small cell lung cancer) following treatment with r(alpha)-IFN. High-performance liquid chromatography (HPLC) profiles of the peptide fractions were compared with those obtained from untreated cells. No significant differences in peptide characteristics (detectable on the basis of retention times) were observed, but significant differences in terms of peptide quantities were observed. Mass spectrometry performed on HPLC peaks allowed not only the detection of three different peptides (two derived from the MAGE family of genes and one from the mart-1) both in untreated and in treated cells, but also gave an indication of the number of peptides within one HPLC peak. This data demonstrates that r(alpha)-IFN-treated cells express a similar peptide pattern as untreated cells, with significant quantitative differences. Interestingly, this finding also explains the higher susceptibility to lysis (mediated by specific cytolytic lymphocytes, which recognize cancer cells in an HLA-restricted fashion) of r(alpha)-IFN-treated cells.
Asunto(s)
Antígenos de Histocompatibilidad Clase I/metabolismo , Interferón-alfa/farmacología , Péptidos/metabolismo , Antígenos de Neoplasias/metabolismo , Antígenos HLA-A/metabolismo , Antígenos HLA-B/metabolismo , Humanos , Células K562 , Antígeno MART-1 , Antígenos Específicos del Melanoma , Proteínas de Neoplasias/metabolismo , Células Tumorales CultivadasRESUMEN
BACKGROUND: Adoptive immunotherapy (AI) of cancer, based upon the injection of in vitro manipulated autologous lymphocytes is still in an experimental phase. Our group started different clinical trials of AI in early 1990, and, at present, some specific targets for this approach seem to have been identified. PATIENTS AND METHODS: 296 patients with solid tumors (melanoma, kidney carcinoma, non-small-cell lung cancer, mesothelioma, neoplastic pleural effusion, and liver cancer) were treated with either locoregional or systemic adoptive immunotherapy (AI) using both LAK and TIL cells in combination with s.c. rIL-2. RESULTS: The surgery/AI combination resulted in good clinical results, characterized by enhanced survival and long lasting disease free periods in a significant number of patients. CONCLUSIONS: AI seems to be efficacious in the treatment of melanoma, lung and hepatic cancers. Further studies will expand the application of the treatment to other malignancies.
Asunto(s)
Inmunoterapia Adoptiva , Células Asesinas Activadas por Linfocinas/trasplante , Linfocitos Infiltrantes de Tumor/trasplante , Neoplasias/terapia , Ensayos Clínicos como Asunto , Humanos , Interleucina-2/uso terapéutico , Neoplasias/mortalidad , Evaluación de Resultado en la Atención de Salud , Tasa de SupervivenciaRESUMEN
It has recently been shown that the infusion of tumor infiltrating lymphocytes (TIL) and recombinant interleukin-2 (rIL-2) in patients operated on for advanced non-small-cell lung cancer (NSCLC), has significant effects in terms of the survival time and control of local relapses. Despite the evident clinical effects, the treatment is unavailable for patients in which TIL have lost their proliferative potential. In an attempt to identify new sources of effector cells using mixed lymphocyte/tumor cultures (MLTC), populations of peripheral blood (PB) lymphoid cells, which have the capability of lysing autologous NSCLC, were studied at the clonal level. Specific cytolytic lymphocytes were detected at very low frequencies in two out of four patients, whereas non-MHC restricted cytolytic T cells were frequently detected. Cytolytic CD4+ belonged to the Th0 or Th2 subsets and were characterized by cytokine secretion patterns suggestive of a lymphokine cascade that could be involved in cancer control. The identification of different efficient effector mechanisms at the clonal level strongly supports the use of in vitro activated lymphocytes, derived from PB, in protocols of adoptive immunotherapy in patients with advanced NSCLC in which TIL are unavailable.